Abstract: The present disclosure provides consumable compositions comprising a haloalkane and a medium chain triglyceride, methods of preparing the consumable composition, and methods of administering the consumable compositions.

Abstract: The present disclosure provides consumable compositions comprising a haloalkane and a medium chain triglyceride, methods of preparing the consumable composition, and methods of administering the consumable compositions.

Abstract: The present disclosure provides consumable compositions comprising a haloalkane and a medium chain triglyceride, methods of preparing the consumable composition, and methods of administering the consumable compositions.

Abstract: The present disclosure provides consumable compositions comprising a haloalkane and a medium chain triglyceride, methods of preparing the consumable composition, and methods of administering the consumable compositions.

Abstract: Compositions for reducing or inhibiting methanogenesis in ruminants comprising, at least one halocarbon compound and one or more stabilising agents.

Abstract: A treatment regime for use in the treatment or prevention of dermatitis and inflammatory skin conditions, said regime comprising the administration of: a) between 50 mg and 3000 mg of a topical liquid or gel composition comprising between 1% w/w and 15% w/w cannabinoid, wherein the cannabinoid is dissolved in the liquid or gel composition.

Abstract: A treatment regime for use in the treatment or prevention of dermatitis and inflammatory skin conditions, said regime comprising the administration of: a) between 50 mg and 3000 mg of a topical liquid or gel composition comprising between 1% w/w and 15% w/w cannabinoid, wherein the cannabinoid is dissolved in the liquid or gel composition.

Abstract: A method for the treatment or prevention of a topical infection by a bacteria of the genus Propionibacterium comprising the step of: administering a therapeutically effective amount of a topical composition comprising a cannabinoid.

Abstract: The use of a composition comprising a cannabinoid, an exemplary cannabinoid is cannabidiol, in the treatment or prevention of an infection by a Neisseria bacterium such as Neisseria gonorrhoea or Neisseria meningitidis.

Abstract: The use of a composition comprising a cannabinoid, that is cannabidiol, in the treatment or prevention of an infection by a Moraxella bacterium such as Moraxella catarrhalis.

Abstract: The use of a composition comprising a cannabinoid, that is cannabidiol, in the treatment or prevention of an infection by a Legionella bacterium such as Legionella pneumophilia.

Abstract: A composition comprising a cannabinoid and a disruptor compound that removes or substantially removes or reduces the integrity of the outer membrane of a bacterium.

Abstract: A topical pharmaceutical composition comprising a solution of 2-(2-ethoxyethoxy)ethanol in a first solvent that is a 2-(2-ethoxyethoxy)ethanol solvent.

Abstract: A pharmaceutical composition comprising a cannabinoid and a siloxane wherein cannabinoid is dissolved in the composition.

Abstract: The present invention provides methods, compositions and uses for treating topical bacterial infections comprising the administration of cannabinoids. In particular, the present invention provides methods, uses and compositions for treating bacterial infections, the compositions comprising cannabidiol or other cannabinoids, in a dose ranging from about 25 mg to about 500 mg of the cannabinoid compounds.

Abstract: A pharmaceutical composition comprising a cannabinoid and a siloxane wherein the cannabinoid is dissolved in the composition.

Abstract: A food processing apparatus comprises a container for food to be processed, the container having a removable cover arranged to engage with the container, and a tool drive for a processing tool, wherein the apparatus is arranged to operate in a first processing mode when the cover is engaged with the container, and is arranged to operate in a second processing mode when the cover is not engaged with the container, in which in the second processing mode, use of the tool drive for processing is restricted with respect to the first processing mode. Thus the apparatus can operate in a ‘safe’ mode when the lid is not engaged.

Abstract: A treatment regime for use in the treatment or prevention of acne, said regime comprising the administration of: a) between 50 mg and 3000 mg of a topical liquid or gel composition comprising between 1% w/w and 15% w/w cannabinoid, wherein the cannabinoid is dissolved in the liquid or gel composition.

Abstract: A treatment regime for use in the treatment or prevention of psoriasis, said regime comprising the administration of: a) between 50 mg and 3000 mg of a topical liquid or gel composition comprising between 1% w/w and 15% w/w cannabinoid, wherein the cannabinoid is dissolved in the liquid or gel composition.

Abstract: A treatment regime for use in the treatment or prevention of dermatitis and inflammatory skin conditions, said regime comprising the administration of: a) between 50 mg and 3000 mg of a topical liquid or gel composition comprising between 1% w/w and 15% w/w cannabinoid, wherein the cannabinoid is dissolved in the liquid or gel composition.